Strides Pharma Science Ltd Faces Mildly Bearish Technical Shift Amid Mixed Momentum Signals

Technical Trend Overview and Price Movement

As of 20 Mar 2026, Strides Pharma’s share price closed at ₹895.75, down 1.03% from the previous close of ₹905.10. The stock traded within a range of ₹890.05 to ₹915.60 during the day, remaining below its 52-week high of ₹1,024.90 but comfortably above the 52-week low of ₹551.00. This price action reflects a cautious market sentiment amid broader sector volatility.

The technical trend has shifted from mildly bullish to mildly bearish, signalling a potential pause or reversal in the recent upward momentum. This is corroborated by the daily moving averages which currently indicate a mildly bearish outlook, suggesting that short-term price averages are beginning to trend lower relative to longer-term averages.

MACD and RSI Signal Analysis

The Moving Average Convergence Divergence (MACD) indicator presents a mildly bearish signal on both weekly and monthly timeframes. This suggests that the momentum behind recent price gains is weakening, with the MACD line likely crossing below the signal line or remaining below it, a classic bearish sign. The monthly MACD’s mildly bearish stance further emphasises a longer-term caution among investors.

Relative Strength Index (RSI) readings add nuance to this picture. On the weekly scale, RSI shows no clear signal, hovering in a neutral zone that neither favours overbought nor oversold conditions. However, the monthly RSI is bearish, indicating that the stock may be losing upward momentum over a longer horizon and could be vulnerable to further downside pressure if selling intensifies.

Bollinger Bands and Other Momentum Indicators

Bollinger Bands provide a somewhat contradictory signal. On the weekly timeframe, they remain mildly bullish, implying that price volatility is contained and the stock is trading near the upper band, which often suggests continued strength. On the monthly timeframe, the bands are bullish, indicating a longer-term trend that still favours upward price movement despite recent weakness.

Other momentum indicators such as the Know Sure Thing (KST) oscillator are bearish on the weekly chart and mildly bearish monthly, reinforcing the notion of waning momentum. Meanwhile, the On-Balance Volume (OBV) indicator is mildly bullish on both weekly and monthly scales, signalling that volume trends still support the stock’s price to some extent, hinting at underlying accumulation despite price softness.

Dow Theory and Moving Averages Context

According to Dow Theory, the weekly timeframe shows no clear trend, reflecting indecision or consolidation in the stock’s price action. Conversely, the monthly Dow Theory assessment is mildly bullish, suggesting that the broader trend remains positive but is currently facing resistance or a corrective phase.

Daily moving averages, which are more sensitive to recent price changes, have turned mildly bearish, indicating that short-term momentum is weakening. This could be a signal for traders to exercise caution or consider defensive positioning until clearer directional cues emerge.

Comparative Returns and Market Context

Strides Pharma’s recent returns present a mixed but generally favourable picture relative to the broader Sensex index. Over the past week, the stock declined by 1.72%, slightly outperforming the Sensex’s 2.40% fall. Over one month, Strides Pharma gained 3.07%, significantly outperforming the Sensex’s 10.05% decline. Year-to-date, the stock is down 0.73%, while the Sensex has fallen 12.92%, highlighting relative resilience.

Longer-term returns are particularly impressive. Over one year, Strides Pharma surged 39.90%, compared to the Sensex’s modest 1.65% decline. Over three years, the stock has delivered a staggering 574.74% return, vastly outpacing the Sensex’s 27.97%. Even over five and ten years, Strides Pharma’s returns of 142.79% and 81.64% respectively, demonstrate strong compounding growth, albeit trailing the Sensex’s 48.84% and 197.39% gains over those periods.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Strides Pharma a Mojo Score of 40.0, categorising it with a Sell grade as of 19 Mar 2026, downgraded from a previous Hold rating. This downgrade reflects the recent deterioration in technical indicators and the cautious outlook from a small-cap perspective. The company’s market cap grade remains small-cap, which typically entails higher volatility and risk compared to larger pharmaceutical peers.

Investors should weigh this technical downgrade alongside the company’s strong historical returns and sector fundamentals. The Pharmaceuticals & Biotechnology sector continues to face regulatory and innovation challenges, which may contribute to the mixed technical signals observed.

Investor Takeaway and Outlook

Strides Pharma Science Ltd’s technical indicators collectively suggest a cautious near-term outlook. The mildly bearish MACD and RSI on monthly charts, combined with daily moving averages turning bearish, point to a potential consolidation or correction phase. However, the bullish signals from Bollinger Bands and OBV on monthly timeframes indicate that underlying buying interest remains, which could support a rebound if market conditions improve.

Given the stock’s strong long-term returns and relative outperformance against the Sensex, investors with a higher risk tolerance may view current weakness as a buying opportunity, particularly if the stock stabilises above key support levels near ₹890. Conversely, more conservative investors might prefer to await clearer confirmation of trend reversal or improvement in momentum indicators before increasing exposure.

Overall, the downgrade to a Sell grade by MarketsMOJO reflects the technical caution warranted at present, but the stock’s fundamental strengths and sector positioning should not be overlooked in a balanced portfolio approach.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today